REINACH, Switzerland--(BUSINESS WIRE)--Vaxxilon AG today announced that Arne von Bonin, PhD has been appointed to the role of Chief Scientific Officer (CSO). Dr. von Bonin is responsible for preclinical and early phase development for Vaxxilon’s multiple projects including the design, implementation and execution of proof of concept and toxicology studies, Phase 1/2 trials and associated regulatory filings.
Dr. von Bonin most recently served as the CSO of Affiris where he worked integrally on technology of active vaccines targeting chronic immune diseases. Before his tenure at Affiris, Dr. von Bonin led a distinguished career at Schering AG and Bayer AG.
Dr. von Bonin is an immunologist by training, having completed his PhD at the Max-Planck Institute for Immunobiology, Freiburg, Germany.
"It’s great to have Arne on board as Vaxxilon’s CSO," said Tom Monroe, CEO of Vaxxilon. "He brings a deep understanding of immunology and broad experience of vaccine development which will benefit Vaxxilon’s portfolio of semi- and fully-synthetic glycoconjugate vaccines, including our preclinical programs in Streptococcus pneumoniae and Haemophilus influenzae type b (Hib)."
Vaxxilon further announced the creation of a Scientific Advisory Board (SAB) and the appointment of Dr. Georg A. Holländer as chair. The Vaxxilon SAB’s role will be to consider, evaluate, and advise on project plans, the medical need and scientific rationale of projects, and long-trends in infectious diseases and immunology.
Dr. Holländer holds dual appointments at the University of Oxford and the University of Basel, where he is the Hoffmann and Action Medical Research Professor of Developmental Medicine and the Professor of Paediatric Immunology, respectively. His research focuses on the development and function of the immune system, in particular that of T cells.
Peter H. Seeberger, scientific founder and a co-inventor of Vaxxilon’s technology, board member, and director of the Max Planck Institute of Colloids and Interfaces commented, “Dr. Holländer is a great addition to Vaxxilon. The breadth and depth of his knowledge and experience plus his enthusiasm for vaccines make him uniquely qualified to lead the SAB.”
Dr. Holländer stated, “I am delighted to be working with Vaxxilon. The medical and scientific need for new and improved vaccines is virtually unlimited. Vaxxilon’s technology has the potential to be applied to many types of pathogens and could fundamentally change vaccines from R&D to production to distribution.”
About Vaxxilon AG
Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon team is advancing several vaccine candidates for the prevention of major infectious diseases.